Computational and experimental advances in drug repositioning for accelerated therapeutic stratification.

Drug repositioning is an important component of therapeutic stratification in the precision medicine paradigm. Molecular profiling and more sophisticated analysis of longitudinal clinical data are refining definitions of human diseases, creating needs and opportunities to re-target or reposition approved drugs for alternative indications. Drug repositioning studies have demonstrated success in complex diseases requiring improved therapeutic interventions as well as orphan diseases without any known treatments. An increasing collection of available computational and experimental methods that leverage molecular and clinical data enable diverse drug repositioning strategies. Integration of translational bioinformatics resources, statistical methods, chemoinformatics tools and experimental techniques (including medicinal chemistry techniques) can enable the rapid application of drug repositioning on an increasingly broad scale. Efficient tools are now available for systematic drug-repositioning methods using large repositories of compounds with biological activities. Medicinal chemists along with other translational researchers can play a key role in various aspects of drug repositioning. In this review article, we briefly summarize the history of drug repositioning, explain concepts behind drug repositioning methods, discuss recent computational and experimental advances and highlight available open access resources for effective drug repositioning investigations. We also discuss recent approaches in utilizing electronic health record for outcome assessment of drug repositioning and future avenues of drug repositioning in the light of targeting disease comorbidities, underserved patient communities, individualized medicine and socioeconomic impact.

[1]  Van V. Brantner,et al.  Estimating the cost of new drug development: is it really 802 million dollars? , 2006, Health affairs.

[2]  Stephen T. C. Wong,et al.  A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy. , 2012, Cancer research.

[3]  David Jou,et al.  Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3). , 2011, Journal of medicinal chemistry.

[4]  Hugh A Barton,et al.  Model-based approaches to predict drug–drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond , 2013, Expert opinion on drug metabolism & toxicology.

[5]  Y. Ff New drugs for old uses and new uses for old drugs , 1959 .

[6]  Pankaj Agarwal,et al.  Systematic Drug Repositioning Based on Clinical Side-Effects , 2011, PloS one.

[7]  F. Iorio,et al.  Transcriptional data: a new gateway to drug repositioning? , 2013, Drug discovery today.

[8]  H. Katus,et al.  Risk stratification and therapeutic decision making in patients with acute coronary syndrome--the role of cardiac troponin T. , 1999, Clinical chemistry and laboratory medicine.

[9]  H. Katus,et al.  Risk Stratification and Therapeutic Decision Making in Patients with Acute Coronary Syndromes the Role of Cardiac Troponin T , 1999 .

[10]  E Harris Antidepressants: Old Drugs, New Uses , 1981, The American journal of nursing.

[11]  J. Y. Wick Psychiatric promise: old drugs, new uses. , 1993, American pharmacy.

[12]  J. Cano,et al.  Human hepatocytes as a keyin vitro model to improve preclinical drug development , 1990, European Journal of Drug Metabolism and Pharmacokinetics.

[13]  T. Scior,et al.  Application of drug repositioning strategy to TOFISOPAM. , 2008, Current medicinal chemistry.

[14]  Yang Liu,et al.  VisANT 4.0: Integrative network platform to connect genes, drugs, diseases and therapies , 2013, Nucleic Acids Res..

[15]  A. Butte,et al.  A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. , 2013, Cancer discovery.

[16]  D. Altshuler,et al.  Validating therapeutic targets through human genetics , 2013, Nature Reviews Drug Discovery.

[17]  R. Weinshilboum,et al.  Pharmacogenetics and pharmacogenomics: development, science, and translation. , 2006, Annual review of genomics and human genetics.

[18]  A. Chiang,et al.  Data‐Driven Methods to Discover Molecular Determinants of Serious Adverse Drug Events , 2009, Clinical pharmacology and therapeutics.

[19]  Jianghong An,et al.  A large-scale computational approach to drug repositioning. , 2006, Genome informatics. International Conference on Genome Informatics.

[20]  C. Chong,et al.  New uses for old drugs , 2007, Nature.

[21]  Hao Ye,et al.  Construction of Drug Network Based on Side Effects and Its Application for Drug Repositioning , 2014, PloS one.

[22]  R. Virmani,et al.  Vascular healing in drug-eluting stents: differential drug-associated response of limus-eluting stents in a preclinical model of stent implantation. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[23]  J. DiMasi New drug development in the United States from 1963 to 1999 , 2001, Clinical pharmacology and therapeutics.

[24]  Julio Saez-Rodriguez,et al.  Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical Properties , 2012, PloS one.

[25]  Joel Dudley,et al.  Network-Based Elucidation of Human Disease Similarities Reveals Common Functional Modules Enriched for Pluripotent Drug Targets , 2010, PLoS Comput. Biol..

[26]  Francis S. Collins,et al.  Mining for therapeutic gold , 2011, Nature Reviews Drug Discovery.

[27]  B. Gallagher,et al.  New therapeutic uses for an old family of drugs: travels of a dental researcher from the lab to the university's office of technology transfer and beyond. , 1996, Technology and health care : official journal of the European Society for Engineering and Medicine.

[28]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[29]  E. Snitkin,et al.  Genome-wide prioritization of disease genes and identification of disease-disease associations from an integrated human functional linkage network , 2009, Genome Biology.

[30]  W. Bisson Drug repurposing in chemical genomics: can we learn from the past to improve the future? , 2012, Current topics in medicinal chemistry.

[31]  F F YONKMAN [New drugs for old uses and new uses for old drugs]. , 1959, Journal - Michigan State Medical Society.

[32]  Philip E. Bourne,et al.  PROMISCUOUS: a database for network-based drug-repositioning , 2010, Nucleic Acids Res..

[33]  Joel Dudley,et al.  Exploiting drug-disease relationships for computational drug repositioning , 2011, Briefings Bioinform..

[34]  K. Dolinski,et al.  Use and misuse of the gene ontology annotations , 2008, Nature Reviews Genetics.

[35]  R. Tagliaferri,et al.  Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.

[36]  Louis A Tartaglia Complementary new approaches enable repositioning of failed drug candidates , 2006, Expert opinion on investigational drugs.

[37]  Richard B. Smith,et al.  Repositioned drugs: integrating intellectual property and regulatory strategies , 2011 .

[38]  Michael Q. Zhang,et al.  Network-based global inference of human disease genes , 2008, Molecular systems biology.

[39]  Deepak K Rajpal,et al.  Applications of Connectivity Map in drug discovery and development. , 2012, Drug discovery today.

[40]  X. Chen,et al.  From phenotype to gene: Detecting disease‐specific gene functional modules via a text‐based human disease phenotype network construction , 2010, FEBS letters.

[41]  Winston Haynes,et al.  Integrative Analysis of Longitudinal Metabolomics Data from a Personal Multi-Omics Profile , 2013, Metabolites.

[42]  J. D. Kleinke The price of progress: prescription drugs in the health care market. , 2001, Health affairs.

[43]  Asher Mullard,et al.  Drug repurposing programmes get lift off , 2012, Nature Reviews Drug Discovery.

[44]  Tao Xu,et al.  Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways , 2013, PLoS Comput. Biol..

[45]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[46]  Philip E. Bourne,et al.  Anti-Infectious Drug Repurposing Using an Integrated Chemical Genomics and Structural Systems Biology Approach , 2013, Pacific Symposium on Biocomputing.

[47]  Walter Kolch,et al.  Systems biology embedded target validation: improving efficacy in drug discovery , 2022 .

[48]  A. Lohse,et al.  Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation , 2012, Hepatology.

[49]  Steven J. M. Jones,et al.  A Computational Approach to Finding Novel Targets for Existing Drugs , 2011, PLoS Comput. Biol..

[50]  Guanghui Hu,et al.  Human Disease-Drug Network Based on Genomic Expression Profiles , 2009, PloS one.

[51]  David C. McPhie Old drugs, new uses: solving a Hatch-Waxman patent predicament. , 2004, Food and drug law journal.

[52]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[53]  Fan Yang,et al.  Drug-target interaction prediction by integrating chemical, genomic, functional and pharmacological data. , 2013, Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing.

[54]  Kelly Chibale,et al.  Drug repositioning in the treatment of malaria and TB. , 2011, Future medicinal chemistry.

[55]  Y. Moreau,et al.  Finding the targets of a drug by integration of gene expression data with a protein interaction network. , 2013, Molecular bioSystems.

[56]  Alexander E. Ivliev,et al.  Drug Target Prediction and Repositioning Using an Integrated Network-Based Approach , 2013, PloS one.

[57]  Ola Spjuth,et al.  Automated QuantMap for rapid quantitative molecular network topology analysis , 2013, Bioinform..

[58]  Michal Magid-Slav,et al.  Identification of Common Biological Pathways and Drug Targets Across Multiple Respiratory Viruses Based on Human Host Gene Expression Analysis , 2012, PloS one.

[59]  Nikolaus Forgó,et al.  Using EHRs to design drug repositioning trials: A devolved approach to data protection , 2014 .

[60]  S. Rees,et al.  Principles of early drug discovery , 2011, British journal of pharmacology.

[61]  Jeffrey Aubé,et al.  Drug repurposing and the medicinal chemist. , 2012, ACS medicinal chemistry letters.

[62]  Kenneth Jung,et al.  Automated Detection of Systematic Off-label Drug Use in Free Text of Electronic Medical Records , 2013, AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science.

[63]  Pankaj Agarwal,et al.  Evaluation of Analytical Methods for Connectivity Map Data , 2012, Pacific Symposium on Biocomputing.

[64]  Khader Shameer,et al.  Functional repertoire, molecular pathways and diseases associated with 3D domain swapping in the human proteome , 2012, Journal of Clinical Bioinformatics.

[65]  Joel Dudley,et al.  Translational Bioinformatics Approaches to Drug Development. , 2013, Advances in wound care.

[66]  L. Cardon,et al.  Use of genome-wide association studies for drug repositioning , 2012, Nature Biotechnology.

[67]  Hong-yu Zhang,et al.  Rational drug repositioning by medical genetics , 2013, Nature Biotechnology.

[68]  Joel T Dudley,et al.  Biomarker and drug discovery for gastroenterology through translational bioinformatics. , 2010, Gastroenterology.

[69]  Yadi Zhou,et al.  Prediction of chemical-protein interactions: multitarget-QSAR versus computational chemogenomic methods. , 2012, Molecular bioSystems.

[70]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[71]  L Lasagna,et al.  New drug development in the United States from 1963 to 1990 , 1991, Clinical pharmacology and therapeutics.

[72]  A. Barabasi,et al.  The human disease network , 2007, Proceedings of the National Academy of Sciences.

[73]  J. An,et al.  Structure-based virtual screening of chemical libraries for drug discovery. , 2006, Current opinion in chemical biology.

[74]  A. Butte,et al.  Network Medicine in Disease Analysis and Therapeutics , 2013, Clinical pharmacology and therapeutics.

[75]  Y. Quan,et al.  Medical genetic inspirations for anticancer drug repurposing. , 2014, Trends in pharmacological sciences.

[76]  M. Schroeder,et al.  Drug repositioning through incomplete bi-cliques in an integrated drug-target-disease network. , 2012, Integrative biology : quantitative biosciences from nano to macro.

[77]  Cui Tao,et al.  Exploring the Pharmacogenomics Knowledge Base (PharmGKB) for Repositioning Breast Cancer Drugs by Leveraging Web Ontology Language (OWL) and Cheminformatics Approaches , 2013, Pacific Symposium on Biocomputing.

[78]  P. Sanseau,et al.  Computational Drug Repositioning: From Data to Therapeutics , 2013, Clinical pharmacology and therapeutics.

[79]  Nonprofit disease groups earmark grants for drug repositioning , 2011, Nature Medicine.

[80]  Mårten Fryknäs,et al.  Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer , 2013, Journal of Cancer Research and Clinical Oncology.

[81]  Albert-László Barabási,et al.  A Dynamic Network Approach for the Study of Human Phenotypes , 2009, PLoS Comput. Biol..

[82]  Brian K. Shoichet,et al.  Virtual screening of chemical libraries , 2004, Nature.

[83]  C. K. Cain,et al.  Annual Reports in Medicinal Chemistry , 2002 .

[84]  R. Sharan,et al.  PREDICT: a method for inferring novel drug indications with application to personalized medicine , 2011, Molecular systems biology.

[85]  Alexander A. Morgan,et al.  Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease , 2011, Science Translational Medicine.

[86]  Y Z Chen,et al.  Predicting targeted polypharmacology for drug repositioning and multi- target drug discovery. , 2013, Current medicinal chemistry.

[87]  Ryen W. White,et al.  Web-scale pharmacovigilance: listening to signals from the crowd , 2013, J. Am. Medical Informatics Assoc..

[88]  Alexander A. Morgan,et al.  Clinical assessment incorporating a personal genome , 2010, The Lancet.

[89]  Lokesh P. Tripathi,et al.  TargetMine, an Integrated Data Warehouse for Candidate Gene Prioritisation and Target Discovery , 2011, PloS one.

[90]  Guangji Wang,et al.  Prediction of human pharmacokinetics from preclinical information of rhein, an antidiabetic nephropathy drug, using a physiologically based pharmacokinetic model. , 2014, Basic & clinical pharmacology & toxicology.

[91]  Steven J. M. Jones,et al.  Drug repositioning for personalized medicine , 2012, Genome Medicine.

[92]  Philip E. Bourne,et al.  Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis , 2009, PLoS Comput. Biol..

[93]  Joel Dudley,et al.  Identification of Discriminating Biomarkers for Human Disease Using Integrative Network Biology , 2008, Pacific Symposium on Biocomputing.

[94]  Winston A Hide,et al.  Big data: The future of biocuration , 2008, Nature.

[95]  A. Brüning Targeting the off-targets: a computational bioinformatics approach to understanding the polypharmacology of nelfinavir , 2011, Expert review of clinical pharmacology.

[96]  Claus Christiansen,et al.  Serological biochemical markers of surrogate efficacy and safety as a novel approach to drug repositioning. , 2011, Drug discovery today.

[97]  Krin A. Kay,et al.  The implications of human metabolic network topology for disease comorbidity , 2008, Proceedings of the National Academy of Sciences.

[98]  Stephen W Michnick,et al.  The connectivity map , 2006, Nature chemical biology.

[99]  K. Tsuda,et al.  Mining Significant Substructure Pairs for Interpreting Polypharmacology in Drug-Target Network , 2011, PloS one.

[100]  Jun Zou,et al.  Advanced Systems Biology Methods in Drug Discovery and Translational Biomedicine , 2013, BioMed research international.

[101]  R. Adolph Old drugs with new uses. Colchicine for treatment of recurrent pericarditis. , 1990, Circulation.

[102]  Alexander A. Morgan,et al.  Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data , 2011, Science Translational Medicine.

[103]  Dima Kozakov,et al.  Hot Spot Analysis for Driving the Development of Hits into Leads in Fragment-Based Drug Discovery , 2012, J. Chem. Inf. Model..

[104]  U. Wolfrum,et al.  Molecular basis of human Usher syndrome: deciphering the meshes of the Usher protein network provides insights into the pathomechanisms of the Usher disease. , 2006, Experimental eye research.

[105]  Paolo Massimo Buscema,et al.  The semantic connectivity map: an adapting self-organising knowledge discovery method in data bases. Experience in gastro-oesophageal reflux disease , 2008, Int. J. Data Min. Bioinform..

[106]  M. DePamphilis,et al.  HUMAN DISEASE , 1957, The Ulster Medical Journal.

[107]  Brendan J. Quinn,et al.  Repositioning metformin for cancer prevention and treatment , 2013, Trends in Endocrinology & Metabolism.

[108]  A. Butte,et al.  Drug Discovery in a Multidimensional World: Systems, Patterns, and Networks , 2010, Journal of cardiovascular translational research.

[109]  Jean Lu,et al.  Functional Module Connectivity Map (FMCM): A Framework for Searching Repurposed Drug Compounds for Systems Treatment of Cancer and an Application to Colorectal Adenocarcinoma , 2014, PloS one.

[110]  Susana Murteira,et al.  Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: reassessment of nomenclature , 2013, Journal of market access & health policy.

[111]  K. Chibale,et al.  Recent developments in rationally designed multitarget antiprotozoan agents. , 2013, Current medicinal chemistry.

[112]  Luonan Chen,et al.  Network-based drug repositioning. , 2013, Molecular bioSystems.

[113]  Scott Parker,et al.  Patenting personalized medicines in the UK, Europe and USA. , 2014, Pharmaceutical patent analyst.

[114]  M. X. Fernandes,et al.  New Uses for Old Drugs: Pharmacophore‐Based Screening for the Discovery of P‐Glycoprotein Inhibitors , 2011, Chemical biology & drug design.

[115]  Justin Lamb,et al.  The Connectivity Map: a new tool for biomedical research , 2007, Nature Reviews Cancer.

[116]  Ralph A. Tripp,et al.  siRNA Genome Screening Approaches to Therapeutic Drug Repositioning , 2013, Pharmaceuticals.

[117]  Clara Campas,et al.  Drug repositioning summit: finding new routes to success. , 2009, Drug news & perspectives.

[118]  Xiaowei Xu,et al.  Investigating drug repositioning opportunities in FDA drug labels through topic modeling , 2012, BMC Bioinformatics.

[119]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[120]  E. Tobinick The value of drug repositioning in the current pharmaceutical market. , 2009, Drug news & perspectives.

[121]  Y Z Chen,et al.  Virtual screening methods as tools for drug lead discovery from large chemical libraries. , 2012, Current medicinal chemistry.

[122]  R. D'Amato,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[123]  K. Thor,et al.  Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. , 1995, The Journal of pharmacology and experimental therapeutics.

[124]  Nigam H. Shah,et al.  Automated Detection of Off-Label Drug Use , 2014, PloS one.

[125]  Yadi Zhou,et al.  Prediction of Chemical-Protein Interactions Network with Weighted Network-Based Inference Method , 2012, PloS one.

[126]  Peng Zhan,et al.  "Old friends in new guise": exploiting privileged structures for scaffold re-evolution/refining. , 2014, Combinatorial chemistry & high throughput screening.

[127]  Cheng Zhu,et al.  Drug repositioning for orphan diseases , 2011, Briefings Bioinform..

[128]  Natalia Novac,et al.  Challenges and opportunities of drug repositioning. , 2013, Trends in pharmacological sciences.

[129]  G. Kaplan,et al.  Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes , 1991, The Journal of experimental medicine.

[130]  Robert Gentleman,et al.  Querying Genomic Databases: Refining the Connectivity Map , 2012, Statistical applications in genetics and molecular biology.

[131]  S. Rajkumar,et al.  The high cost of cancer drugs and what we can do about it. , 2012, Mayo Clinic proceedings.

[132]  M. Ramanathan,et al.  Network‐Based Approaches in Drug Discovery and Early Development , 2013, Clinical pharmacology and therapeutics.

[133]  Ivan Molineris,et al.  Drug repositioning for orphan genetic diseases through Conserved Anticoexpressed Gene Clusters (CAGCs) , 2013, BMC Bioinformatics.

[134]  Mathewson Ma New uses for old drugs: vasodilators (CEU home study). , 1982 .

[135]  Noor B. Dawany,et al.  Bioinformatics analysis reveals transcriptome and microRNA signatures and drug repositioning targets for IBD and other autoimmune diseases , 2012, Inflammatory bowel diseases.

[136]  T. Enomoto,et al.  Therapeutic strategies in epithelial ovarian cancer , 2012, Journal of Experimental & Clinical Cancer Research.

[137]  A J Atkinson,et al.  Panel on public service drugs and new uses for old drugs , 1975, Clinical pharmacology and therapeutics.

[138]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[139]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[140]  Patricia McGrath,et al.  Zebrafish: a preclinical model for drug screening. , 2002, Assay and drug development technologies.

[141]  Hugo Y. K. Lam,et al.  Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes , 2012, Cell.

[142]  Giorgio Valentini,et al.  Network-Based Drug Ranking and Repositioning with Respect to DrugBank Therapeutic Categories , 2013, IEEE/ACM Transactions on Computational Biology and Bioinformatics.

[143]  Ramaiah Muthyala,et al.  Orphan/rare drug discovery through drug repositioning , 2011 .

[144]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[145]  Yong Wang,et al.  Network predicting drug's anatomical therapeutic chemical code , 2013, Bioinform..

[146]  New ways to take old drugs. , 1998, STEP perspective.